MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MWPC005, a topically applied biological drug candidate that is in Phase I/II clinical trial for the treatment of non-melanoma skin cancers; and MWPC003 for connective tissue disorders. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
IPO Year: 2014
Exchange: NASDAQ
Website: mediwound.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/2/2025 | $25.00 | Buy | Alliance Global Partners |
| 2/28/2025 | $39.00 | Buy | Craig Hallum |
| 7/16/2024 | $25.00 → $30.00 | Buy | Maxim Group |
| 12/22/2022 | $11.00 | Buy | Maxim Group |
| 7/18/2022 | $7.00 | Outperform | Oppenheimer |
| 8/17/2021 | $10.00 → $9.00 | Buy | Aegis Capital |
| 8/11/2021 | $7.00 → $6.50 | Buy | HC Wainwright & Co. |
VALUE Phase III trial of EscharEx® in venous leg ulcers advancing as planned NexoBrid® manufacturing expansion on track; full operational capacity expected by year-end 2025 First quarter revenue of $4 million; full-year 2025 revenue guidance reaffirmed at $24 million Conference call today, May 21 at 8:30am Eastern Time YAVNE, Israel, May 21, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the first quarter ended March 31, 2025, and provided a corporate update. "We entered 2025 with strong execution across our clinical, commercial, and operational priorities, mainta
YAVNE, Israel, May 05, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will report financial results for the first quarter ended March 31, 2025 on Wednesday, May 21, 2025. Following the release, MediWound's management will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss these financial results and provide corporate updates. Dial-in and call details are as follows: Conference Call & Webcast DetailsToll-Free:1-844-676-8833Israel:1-80-921-2373International:1-412-634-6869Webcast:Click HERE To access the call, participan
Initiated VALUE, a global Phase III pivotal trial of EscharEx® for venous leg ulcers Expanded strategic research collaborations with industry leaders, now including Kerecis $20 million in revenue for 2024; $24 million projected for 2025; $44 million in cash as of Year-End 2024 Conference call today, March 19 at 8:30am Eastern Time YAVNE, Israel, March 19, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the fourth quarter and full year ended December 31, 2024, and provided a corporate update. "2024 was a pivotal year for MediWound, marked by strong execution, clinica
YAVNE, Israel, March 03, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2024 on Wednesday, March 19, 2025. Following the release, MediWound's management will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss these financial results and provide corporate updates. Dial-in and call details are as follows: Conference Call & Webcast DetailsToll-Free: 1-833-630-1956Israel: 1-80-921-2373International: 1-412-317-1837Webcast: Click HERE To access the call, partici
EscharEx IND Submission by Year-End; Phase 3 Study to Begin Shortly Thereafter; KOL Event Set for January 8, 2025 FDA Approves NexoBrid for Pediatric Use $25 Million Financing and €16.25 Million EIC Funding Strengthen Cash Runway to Profitability NexoBrid Product Revenue Meets Expectations; Demand Exceeds Capacity as New Manufacturing Facility Commissioning Underway Conference Call Today, November 26 at 8:30 a.m. Eastern Time YAVNE, Israel, Nov. 26, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the third quarter ended September 30, 2024, and p
YAVNE, Israel, Nov. 12, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will release its financial results for the third quarter ended September 30, 2024, on Tuesday, November 26, 2024. Following the release, MediWound's management will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss these financial results and provide corporate updates. Dial-in and call details are as follows: Conference Call & Webcast DetailsToll-Free:1-833-630-1956Israel:1-80-921-2373International:1-412-317-1837Webcast:Click HERE To access the call, participants should dial the app
Completed Construction of New NexoBrid® Manufacturing Facility €16.25 Million EIC Funding Expedites EscharEx® Development for Diabetic Foot Ulcers, Significantly Expanding the Addressable Market; Phase III Study for Venous Leg Ulcers to Begin in H2 2024 $25 Million Strategic Investment Led by Mölnlycke Health Care Conference Call Today, August 14 at 8:30am Eastern Time YAVNE, Israel, Aug. 14, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the second quarter ended June 30, 2024, and provided a corporate update. "This has been another
YAVNE, Israel, Aug. 02, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the Company will release its financial results for the second quarter ended June 30, 2024 on Wednesday, August 14, 2024. Following the release, management will host a conference call and live webcast at 8:30 am Eastern Time to discuss the financial results, provide corporate updates, and answer questions. Dial-in and call details are as follows: Conference Call & Webcast DetailsToll-Free:1-833-630-1956Israel:1-80-921-2373International:1-412-317-1837Webcast:Click HERE To access the call, participants should dial
NexoBrid® interest surges; $5 million in Q1 2024 revenue, with $24 million forecast for the year Manufacturing facility on target for completion by mid-2024 EscharEx® Phase III study to launch 2H 2024 Company set to join Russell 3000® Index Conference call today, May 29 at 8:30am Eastern Time YAVNE, Israel, May 29, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the first quarter ended March 31, 2024, and provided a corporate update. "During the first quarter we maintained a laser-focused approach to executing our strategic plan. At the beginning of the year, w
YAVNE, Israel, May 22, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the Company will release its financial results for the first quarter ended March 31, 2024 on Wednesday, May 29, 2024. Following the release, management will host a conference call and live webcast at 8:30 am Eastern Time to discuss the financial results, provide corporate updates, and answer questions. Dial-in and call details are as follows: Conference Call & Webcast DetailsToll-Free:1-833-630-1956Israel:1-80-921-2373International:1-412-317-1837Webcast:Click HERE To access the call, participants should dial th
SC 13G/A - MediWound Ltd. (0001593984) (Subject)
SC 13G/A - MediWound Ltd. (0001593984) (Subject)
SC 13G - MediWound Ltd. (0001593984) (Subject)
SC 13D - MediWound Ltd. (0001593984) (Subject)
SC 13D/A - MediWound Ltd. (0001593984) (Subject)
SC 13G/A - MediWound Ltd. (0001593984) (Subject)
SC 13G/A - MediWound Ltd. (0001593984) (Subject)
SC 13G/A - MediWound Ltd. (0001593984) (Subject)
SC 13G/A - MediWound Ltd. (0001593984) (Subject)
SC 13G/A - MediWound Ltd. (0001593984) (Subject)
Alliance Global Partners initiated coverage of MediWound with a rating of Buy and set a new price target of $25.00
Craig Hallum initiated coverage of MediWound with a rating of Buy and set a new price target of $39.00
Maxim Group reiterated coverage of MediWound with a rating of Buy and set a new price target of $30.00 from $25.00 previously
Maxim Group initiated coverage of MediWound with a rating of Buy and set a new price target of $11.00
Oppenheimer resumed coverage of MediWound with a rating of Outperform and set a new price target of $7.00
Aegis Capital reiterated coverage of MediWound with a rating of Buy and set a new price target of $9.00 from $10.00 previously
HC Wainwright & Co. reiterated coverage of MediWound with a rating of Buy and set a new price target of $6.50 from $7.00 previously
Aegis initiated coverage of MediWound with a rating of Buy and set a new price target of $10.00
Aegis Capital initiated coverage of MediWound with a rating of Buy and set a new price target of $10.00
HC Wainwright resumed coverage of MediWound with a rating of Buy and set a new price target of $7.00 from $5.50 previously
YAVNE, Israel, Nov. 21, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced the appointment of Shmulik Hess, Ph.D. to the positions of Chief Operating Officer and Chief Commercial Officer effective as of December 1, 2023. Dr. Hess will lead and oversee all operational and commercial activities at MediWound. "We are delighted to welcome Shmulik, a distinguished industry executive, to our team. Dr. Hess joins MediWound during a crucial phase of expansion as we diligently implement our global strategy. Given Shmulik's outstanding track record in international o
YAVNE, Israel, and DENKENDORF, Germany, Nov. 08, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, and PolyMedics Innovations (PMI), an innovative biomaterials company specializing in effective wounds treatment, today announced an agreement for the promotion of NexoBrid® in Germany, Austria, Belgium, the Netherlands and Luxemburg. Feedback from key opinion leaders and customers indicates that NexoBrid, a non-surgical solution for eschar removal in burns, is a perfect complement to PMI's existing product line, including SUPRATHEL®, NovoSorb® BTM, and SUPRA SDRM®. Along wit
YAVNE, Israel, March 16, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a fully integrated biopharmaceutical company specializing in next-generation biotherapeutic solutions for tissue repair and regeneration, is pleased to announce the appointment of Ms. Hani Luxenburg as its new Chief Financial Officer, effective May 14, 2023. Ms. Luxenburg will replace Mr. Boaz Gur-Lavie, who has served as MediWound's Chief Financial Officer for the past four years. Mr. Gur-Lavie will remain with the Company through July 31, 2023 to ensure an orderly transition. With over 20 years of progressive leadership experience managing financial and accounting operations, Ms. Luxenburg joins MediWound wi
Appoints Barry Wolfenson, as Executive Vice President of Strategy and Corporate Development Appoints Alicia Torrenova, as Vice President of European Operations Both bring extensive leadership experience and expertise in wound care and regenerative medicine YAVNE, Israel, March 06, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD) (the "Company"), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced the appointment of Barry Wolfenson as Executive Vice President of Strategy & Corporate Development. In this role, Mr. Wolfenson will be responsible for the Company's global strategic plan, busi
YAVNE, Israel, June 30, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced the appointment of Mr. Tzvi Palash as Chief Operating Officer (COO). Mr. Palash will be responsible for leading all operational activities at MediWound. "We are thrilled to welcome Tzvi, a seasoned industry veteran to our team. He brings extensive experience in operations, with a proven track record of successfully executing at critical periods throughout a company's journey," said Ofer Gonen, CEO of MediWound. "I am pleased that we have been able to attract such
Ofer Gonen, current Board member and CEO of Clal Biotechnology Industries Ltd., appointed as New CEO – Effective June 30 Will replace current CEO Sharon Malka, who will join the Board of Directors YAVNE, Israel, May 17, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced the appointment of Ofer Gonen as Chief Executive Officer (CEO) of MediWound as of June 30, 2022, succeeding Sharon Malka, who will join the Company's Board of Directors. Ofer Gonen has been a board member in MediWound and the CEO of Clal Biotechnology Industries, Ltd. ("C
VALUE Phase III trial of EscharEx® in venous leg ulcers advancing as planned NexoBrid® manufacturing expansion on track; full operational capacity expected by year-end 2025 First quarter revenue of $4 million; full-year 2025 revenue guidance reaffirmed at $24 million Conference call today, May 21 at 8:30am Eastern Time YAVNE, Israel, May 21, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the first quarter ended March 31, 2025, and provided a corporate update. "We entered 2025 with strong execution across our clinical, commercial, and operational priorities, mainta
YAVNE, Israel, May 13, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced the publication of a peer-reviewed post hoc analysis in Wounds. The analysis is based on data from the Company's Phase II ChronEx clinical trial in patients with venous leg ulcers (VLUs) evaluating the efficacy and safety of EscharEx® compared with collagenase ointment (SANTYL®), the only FDA-cleared enzymatic debridement agent commercially available for the treatment of dermal ulcers. The article, titled "Bromelain-Based Debridement Versus Collagenase Ointment Debridement of Venous Leg Ulcers: Post Hoc Analysis of
YAVNE, Israel, May 05, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will report financial results for the first quarter ended March 31, 2025 on Wednesday, May 21, 2025. Following the release, MediWound's management will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss these financial results and provide corporate updates. Dial-in and call details are as follows: Conference Call & Webcast DetailsToll-Free:1-844-676-8833Israel:1-80-921-2373International:1-412-634-6869Webcast:Click HERE To access the call, participan
Presentations at WHS and SAWC to highlight EscharEx's mechanism of action, preclinical advantages over SANTYL®, and new data in treating VLUs and DFUs Findings reinforce the ongoing Phase III study in VLUs and support the planned DFU trial strategy YAVNE, Israel, April 28, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will present 10 scientific abstracts—including both oral and poster presentations—at two of the world's premier wound care conferences: the Wound Healing Society (WHS) and the Symposium on Advanced Wound Care (SAWC) Spring 2025, taking place April 30
Initiated VALUE, a global Phase III pivotal trial of EscharEx® for venous leg ulcers Expanded strategic research collaborations with industry leaders, now including Kerecis $20 million in revenue for 2024; $24 million projected for 2025; $44 million in cash as of Year-End 2024 Conference call today, March 19 at 8:30am Eastern Time YAVNE, Israel, March 19, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the fourth quarter and full year ended December 31, 2024, and provided a corporate update. "2024 was a pivotal year for MediWound, marked by strong execution, clinica
YAVNE, Israel, March 03, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2024 on Wednesday, March 19, 2025. Following the release, MediWound's management will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss these financial results and provide corporate updates. Dial-in and call details are as follows: Conference Call & Webcast DetailsToll-Free: 1-833-630-1956Israel: 1-80-921-2373International: 1-412-317-1837Webcast: Click HERE To access the call, partici
Findings in Burns Journal confirm NexoBrid's superiority over standard of care in pediatric patients with deep thermal burnsNexoBrid is approved for pediatric use in the U.S., E.U. and Japan YAVNE, Israel, Feb. 25, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced the publication of its Phase III Children Innovative Debridement Study (CIDS) in Burns, the peer-reviewed Journal of the International Society for Burn Injuries (ISBI). The study evaluated the efficacy and safety of NexoBrid® compared to the standard of care (SOC) in pediatric patients with deep partial- and full-thickness thermal b
YAVNE, Israel, Feb. 24, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Chief Executive Officer Ofer Gonen will present a corporate overview at the upcoming 45th Annual TD Cowen Health Care Conference, taking place in Boston, MA on Wednesday, March 5, 2025, at 11:50 AM ET. To listen to the live webcast of the presentation, please register here. A replay of the event will also be posted to MediWound's website on the Events & Presentations page of the Investors section. In addition, the MediWound management team will host one-on-one meetings during the conference. Interested investors a
Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closure Interim analysis planned after 65% of patients complete treatment, expected in mid-2026 Strategic research collaborations with Solventum, Mölnlycke, and MIMEDX YAVNE, Israel, Feb. 12, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced the initiation of VALUE, a global, pivotal Phase III trial evaluating EscharEx® for the treatment of venous leg ulcers (VLUs). "We are proud to initiate the VALUE study, the most comprehensive VLU trial in over a decade," said Ofer Gonen, Ch
YAVNE, Israel, Feb. 04, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Chief Executive Officer Ofer Gonen will take part in a fireside chat during the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual). The fireside chat, hosted by Francois Brisebois, Managing Director, Senior Biotechnology Research Analyst at Oppenheimer, will take place on Wednesday, February 12, 2025 at 8:00 AM ET. To attend the virtual fireside chat, please register here. A webcast link to access the fireside chat will also be posted to MediWound's website on the Events & Presentations
Submission status for MEDIWOUND, LTD's drug NEXOBRID (SUPPL-10) with active ingredient ANACAULASE-BCDB has changed to 'Approval' on 08/15/2024. Application Category: BLA, Application Number: 761192, Application Classification:
Submission status for MEDIWOUND, LTD's drug NEXOBRID (ORIG-1) with active ingredient ANACAULASE-BCDB has changed to 'Approval' on 12/28/2022. Application Category: BLA, Application Number: 761192, Application Classification:
Submission status for MEDIWOUND, LTD's drug NEXOBRID (SUPPL-1) with active ingredient ANACAULASE-BCDB has changed to 'Approval' on 12/28/2022. Application Category: BLA, Application Number: 761192, Application Classification:
6-K - MediWound Ltd. (0001593984) (Filer)
6-K - MediWound Ltd. (0001593984) (Filer)
6-K - MediWound Ltd. (0001593984) (Filer)
424B3 - MediWound Ltd. (0001593984) (Filer)
EFFECT - MediWound Ltd. (0001593984) (Filer)
F-3 - MediWound Ltd. (0001593984) (Filer)
S-8 - MediWound Ltd. (0001593984) (Filer)
20-F - MediWound Ltd. (0001593984) (Filer)
6-K - MediWound Ltd. (0001593984) (Filer)
6-K - MediWound Ltd. (0001593984) (Filer)